AstraZeneca and Lilly put PARP1 and KRAS G12C inhibitors into their first phase 3s, while Amgen advances DLL3 into early-stage disease.

Akeso’s cadonilimab hits in its first-line study, but there’s no US data and no US partner.

A domvanalimab triplet shows some promise in high PD-L1-expressing gastric cancer patients, but caveats abound.

Arcellx climbs 19%, but the most significant Car-T presentation at ASH might not even be in oncology.

The upcoming ASH conference will feature rival datasets from inhibitors of Menin, KIT, EZH1/2, BTK, BET, BCR/ABL and more.

Meanwhile, Bristol Myers Squibb hands back two mystery projects.

Assets targeting PSMA and KRAS G12V, plus another gamma-delta Car-T therapy, feature among recently disclosed first-time clinical trial entrants.

But efficacy still needs to go up, as several groups try to combine PD-1 and CTLA-4 using differing approaches.